E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Hereditary angioedema type I and type II |
|
E.1.1.1 | Medical condition in easily understood language |
Hereditary angioedema (HAE) |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Immune system processes [G12] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 23.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10019860 |
E.1.2 | Term | Hereditary angioedema |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10080956 |
E.1.2 | Term | Hereditary angioedema type I |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10080960 |
E.1.2 | Term | Hereditary angioedema type II |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to assess the pharmacokinetic (PK) characteristics of OCTA-C1-INH after a single intravenous (IV) administration in HAE patients who are not experiencing an HAE attack. |
|
E.2.2 | Secondary objectives of the trial |
• To assess blood level changes of C1-INH antigen and C4 level after a single IV administration of OCTA-C1-INH. • To assess the safety of OCTA-C1-INH IV administration. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Documented congenital C1-INH deficiency with C1-INH functional activity less than 50% and C4 level below the laboratory reference range. 2. Age ≥18 years at informed consent date. 3. Signed informed consent. 4. Patient must be capable to understand and comply with the relevant aspects of the study protocol. 5. Women of childbearing potential must have a negative pregnancy test at screening as well as pre-infusion and must agree to use acceptable methods of contraception from screening until final visit. 6. Fertile male patients must agree to use acceptable methods of contraception from screening until final visit. |
|
E.4 | Principal exclusion criteria |
1. Any signs of an HAE attack OR HAE attack within 7 days prior to dosing with the IMP (OCTA-C1-INH) OR more than a total of 9 HAE attacks over the previous 3 months prior to dosing with the IMP. 2. Patients who have received prophylactic or acute treatment with C1-INH (Berinert®, Cinryze®, HAEgarda®, Ruconest®, etc.), non-biological bradykinin pathway inhibitors (e.g., ecallantide, icatibant), or treatment with tranexamic acid within 2 weeks prior to dosing with the IMP. 3. Patients who have received treatment with lanadelumab within 11 weeks prior to dosing with the IMP. 4. Patients with planned dental, medical, or surgical procedures who will need pre-procedural HAE prophylaxis during the study period. 5. Female patients taking estrogen-containing contraceptive regimen, hormone replacement therapy (excepting progesterone-only contraceptives, which are permitted), or selective estrogen receptor modulators (e.g., tamoxifen). Any patients on specific androgen therapy (e.g., testosterone, danazol, dehydroepiandrosterone/androstenedione). 6. Any change (start, stop, or change in dose) in androgen therapy (e.g., oxandrolone, stanozolol) in the last 14 days prior to dosing with the IMP. 7. Participated in any other investigational drug evaluation or received blood or a blood product, except for C1-INH, within 30 days prior to dosing with the IMP. 8. Live viral vaccination within 30 days prior to screening. 9. Acute infectious illness characterized by rapid onset of disease, a relatively brief period of symptoms, and resolution within a short period of time. 10. Risk factors for thromboembolic events, including presence of indwelling venous catheter or access device, history of thrombosis, underlying atherosclerosis, morbid obesity (defined as BMI of ≥35 kg/m2 and experiencing obesity-related health conditions or ≥40 to 44.9 kg/m2), immobility, or medications known to increase thromboembolic risk. 11. History of allergic reaction to C1-INH products or other blood products. 12. History of clinically relevant antibody development against C1-INH. 13. Any history of B-cell malignancy that was unresolved in the past 5 years. 14. Pregnancy or lactation. 15. Any clinically significant medical or psychiatric condition that, in the opinion of the Investigator, would interfere with the patient’s ability to participate in the study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is the PK parameters of OCTA-C1-INH, measured as C1-INH activity. The PK parameters that will be assessed for OCTA-C1-INH include: • Blood concentrations at each sampling time • Maximum blood concentration (Cmax) • Time to maximum concentration (Tmax) • Clearance (CL) • Area under the concentration-time curve (AUC) • AUC normalized by the dose (AUCnorm) • Mean residence time (MRT) • Incremental recovery (IR) • Volume of distribution (Vd) • Elimination half-life (T1/2) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
PK sampling (pre-injection, post-injection: at 0 and 15 minutes, 1 hour, 2, 6, 12, 24, 48, 72, 120, 144, and 168 hours) |
|
E.5.2 | Secondary end point(s) |
• PK parameters of the following analytes: - C1-INH antigen - C4 level All PK parameters determined for the primary PK endpoint will also be determined for the secondary PK endpoints. • Safety Parameters: - Number and severity of adverse events of special interest (AESIs) of thromboembolic event (TEE) type - Change in vital signs from pre- to post-injection - Change in laboratory parameters from pre- to post-injection - Serology testing, blood nuclear antigen tests for hepatitis A virus [HAV], hepatitis B virus [HBV], hepatitis C virus [HCV], human immunodeficiency virus [HIV]-1/2, and parvovirus B19 - Anti-C1-INH antibodies |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
PK sampling (pre-injection, post-injection: at 0 and 15 minutes, 1 hour, 2, 6, 12, 24, 48, 72, 120, 144, and 168 hours) safety (at all visits from the timepoint of injection until end of study) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 1 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Belarus |
Russian Federation |
Ukraine |
Germany |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |